-
NEJM Releases Bayer Key Phase 3 Clinical Results: DKD Progress Slows 18% CV Risk reduction by 14%
Time of Update: 2020-11-11
) by overactivated salt corticosteroids. Finerenone is a research nonsteroidal selective salt corticosteroid (MR) antagonist that reduces the harmful effects of overactivation of salt corticosteroids. FIDELIO-DKD is a randomized, double-blind
-
Micropropagation and Organogenesis of Anthurium andreanum Lind cv Rubrun
Time of Update: 2020-11-10
We also describe a detailed method for the histological analysis of callus tissue and a vitro plants acclimatization protocol.
-
Oxford University study of 420,000 people: The earlier you correct this bad habit, the lower the risk of CV death
Time of Update: 2020-11-09
death from cardiovascular disease than people who never smoke, and the lower the risk of starting smoking, the lower the risk; researchers from the University of Oxford in the United Kingdom followed up with more than 420,000 subjects
-
When CVS announced that it would replace biological analogues in its health care catalog from next year
Time of Update: 2016-08-09
The company also said it no longer reimbursed toujeo, Sanofi's new diabetes drug.
-
CVs, an American drugstore chain giant, is holding hands with three telemedicine companies
Time of Update: 2015-08-28
Source: health industry on August 26, 2015, CVS health, an American drugstore giant, announced that it would cooperate with three major telemedicine companies: American well
-
Gilead can't help but fight back: CVS supplies Gilead hepatitis C drugs exclusively
Time of Update: 2015-01-07
Source: e-medicine Facebook 2015-1-7 CVS said that unless medical treatment requires special circumstances or prior authorization, the all oral hepatitis C drug combination viekira
-
CVs, the second largest pharmacy in the United States, spent $2.1 billion on medical and health services
Time of Update: 2013-11-28
Source: financial China News Agency announced on November 28, 2013 that CVS Caremark, the second largest pharmacy group in Dalian in the United States, spent $2.1 billion to acquire Coram, a special injection service provider, from Apria healthcare group.
